The existence of PLK1-mediated FOXO1 inhibition in human advanced PCa cells and the effectiveness of inhibition of PLK1 in reversing this process highlight the therapeutic potential of targeting PLK1-FOXO1 signaling for the treatment of advanced PCa. The gene discussed is FOXO1; the disease is posterior cortical atrophy.